National Eye Institute; Notice of Closed Meeting, 8266 [2012-3432]
Download as PDF
<![CDATA[
8266
Federal Register / Vol. 77, No. 30 / Tuesday, February 14, 2012 / Notices
bypasses the human metabolic
machinery needed to convert the drug
into its active metabolite(s).
• Decreased CNS side effects.
Development Stage: In vivo data
available (animal).
Inventors: Irving W. Wainer, Ph.D.
(NIA), Carlos A. Zarate, M.D. (NIMH),
Ruin Moaddel, Ph.D. (NIA), Michel
Bernier (NIA), Michael E. Goldberg,
M.D., Marc C. Toriman, Ph.D.
Publications:
1. Moaddel R, et al. A parallel chiralachiral liquid chromatographic
method for the determination of the
stereoisomers of ketamine and
ketamine metabolites in the plasma
and urine of patients with complex
regional pain syndrome. Talanta.
2010 Oct. 15;82(5):1892–1904.
[PMID 20875593]
2. Zarate CA Jr., et al. Relationship of
Ketamine’s Plasma Metabolites with
Response and Diagnosis, and Side
Effects in Major Depression.
Manuscript in preparation.
3. Ibrahim L, et al. Course of
Improvement in Depressive
Symptoms to a Single Intravenous
Infusion of Ketamine vs. Add-on
Riluzole: Results from a Four-Week,
Double-Blind, Placebo-Controlled
Study. Neuropsychopharmacology,
in press.
4. Zhao X, et al. Population
Pharmacokinetic Modeling of
Ketamine and Three Major
Metabolites in Patients with
Treatment-Resistant Bipolar
Depression. Br. J. Clin. Phamaco., in
press.
Intellectual Property: HHS Reference
No. E–092–2011/0—U.S. Provisional
Application No. 61/547,336 filed 14
Oct. 2011.
mstockstill on DSK4VPTVN1PROD with NOTICES
Jkt 226001
Dated: February 8, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
BILLING CODE 4140–01–P
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended,
for the review, discussion, and
evaluation of individual intramural
PO 00000
Frm 00054
Fmt 4703
programs and projects conducted by the
National Eye Institute, including
consideration of personnel
qualifications and performances, and
the competence of individual
investigators, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Eye Institute.
Date: March 4–5, 2012.
Time: 7:00 PM to 5:00 PM.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Contact Person: Sheldon S. Miller, Ph.D.,
Scientific Director, National Institutes of
Health, National Eye Institute, Bethesda, MD
20892, (301) 451–6763.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
www.nei.nih.gov, where an agenda and any
additional information will be posted when
available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: February 8, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–3432 Filed 2–13–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Licensing Contact: Jaime M. Greene,
M.S.; 301–435–5559;
greenejaime@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute on Aging,
Laboratory of Clinical Investigation,
Bioanalytical Chemistry and Drug
Discovery Section, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Nicole Guyton, Ph.D. at
darackn@mail.nih.gov.
21:57 Feb 13, 2012
Description of Technology: Nucleic
acid based vaccines are attractive
alternatives to conventional vaccines for
a number of reasons. One of the issues
with nucleic acid based vaccines is the
poor immunogenicity in humans. The
subject technology is a method for
eliciting improved immune responses
with DNA based vaccines. The method
involves co-administration of a nucleic
acid vaccine with a protein vaccine for
the same antigen of interest that is
encoded by the DNA vaccine in a primeboost protocol. This methodology
increased the immune responses in a
SIV macaque model to examine DNA
based vaccines of HIV and vaccine
protocols. The methodology can
potentially be applied to other disease
indications to elicit greater immune
responses.
Potential Commercial Applications:
Improve immunogenicity of nucleic
acid based vaccines.
Competitive Advantages: The
methodology increases the immune
response of DNA based vaccines.
Development Stage:
• Early-stage
• Pre-clinical
• In vitro data available
• In vivo data available (animal)
Intellectual Property: HHS Reference
No. E–239–2009/0—International PCT
Application No. PCT/US2011/026325
filed 25 Feb. 2011.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
[FR Doc. 2012–3412 Filed 2–13–12; 8:45 am]
Related Technologies: HHS Reference
No. E–174–2006/0—
• U.S. Patent Application No. 11/
688,603 filed 20 Mar. 2007
• Related international applications
VerDate Mar<15>2010
Improved DNA-Protein Vaccination
Protocols
Sfmt 4703
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\14FEN1.SGM
14FEN1
]]>Agencies
[Federal Register Volume 77, Number 30 (Tuesday, February 14, 2012)]
[Notices]
[Page 8266]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-3432]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended,
for the review, discussion, and evaluation of individual intramural
programs and projects conducted by the National Eye Institute,
including consideration of personnel qualifications and performances,
and the competence of individual investigators, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, National Eye
Institute.
Date: March 4-5, 2012.
Time: 7:00 PM to 5:00 PM.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Sheldon S. Miller, Ph.D., Scientific Director,
National Institutes of Health, National Eye Institute, Bethesda, MD
20892, (301) 451-6763.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: www.nei.nih.gov, where an agenda and any additional
information will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.867,
Vision Research, National Institutes of Health, HHS)
Dated: February 8, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-3432 Filed 2-13-12; 8:45 am]
BILLING CODE 4140-01-P
